Poxel Announces Participation in Two Upcoming Investor Conferences

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it will be featured as a presenting company at the Jefferies 2016 London Healthcare Conference and will be available for meetings at the Oppenheimer 2016 Life Sciences Summit. The Jefferies 2016 London Healthcare Conference is being held from November 16-17th at The Waldorf Hilton Hotel in London and the Oppenheimer 2016 Life Sciences Summit will be held on November 29th at the Sofitel Hotel in New York City.

Thomas Kuhn, CEO of Poxel, will provide an overview of the Company's business at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16th at 1:20 pm GMT and will be available to participate in one-on-one meetings with investors. The Company’s management team will also be available for one-on-one meetings at the Oppenheimer 2016 Life Sciences Summit on November 29th.

The presentation will be webcast live. To access the webcast, please visit the following link http://wsw.com/webcast/jeff100/poxel.pa. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005796/en/

Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior Vice President, Investor Relations and Public Relations
[email protected]
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 175 571 1562
[email protected]
or
Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
[email protected]

Source: Poxel SA

You May Also Be Interested In

• Jefferies: Used business jet inventories drop 45% year-over-year in August
• GameChange Energy completes commissioning of its Genius Tracker™ for Dannevirke Solar Farm in New Zealand
• The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1